Archive for the Stomach Cancer category.
The treatment of gastric cancer is really surgical resection. This just shows you the stomach. Again, as a general rule, in the GI tract the organs are – except for the liver and the pancreas – are really hollow visci. In mammals hollow visci are hung on a lymphovascular pedicle. So you have this lymphovascular pedicle and surgical management of gastric cancer entails removing the tumor wherever it happens to be, with a wide margin and also taking some of the lymph nodes. Now how many lymph nodes you take and whether or not you increase the cure by taking a more extensive lymph node dissection is one of the areas of real contention in gastric cancer. One of the areas where, within the last year for example, there’s been important literature published to discuss this problem. Basically, with gastric cancer you can refer to the N1 nodes. And if tumor, for example, were here in the distal stomach the N1 nodes would be nodes within 3 cm of the tumor. The N2 nodes are nodes greater than 3 cm and are typically the celiac access nodes or the hepatic portal nodes or the splenic nodes. You will hear about a R1 resection or a D1 or D2 dissection, and what that means; a R1 or D1 dissection takes the N1 nodes. A D2 dissection would take the N2 nodes in continuity with the tumor. So an en bloc resection. This just shows you a U.S. data from about 10 years ago, American College of Surgery data, on gastric cancer survival with surgery. If you had very early disease, and Ia is essentially mucosal gastric cancer – rarely seen in this country – surgery is highly curative. If you have the typical gastric cancers seen in this country, which are node-positive, IIIa, IIIb, the chance of survival with surgery alone is somewhere around 20%. So there is a high risk of recurrence and that of course is the treatment of microscopic residual disease with curative intent, of course it is adjuvant therapy. But surgery for the typical patient who is diagnosed in this country, who has relatively locally advanced gastric cancer, surgery may cure at best 20% of patients.
Cialis professional
This just shows you what I went over before. The literature has changed so this slide is a little bit old. These should really be D0, D1, D2 rather than R1, but what it refers to is the type of nodal dissections. This is the one that is of quite interest. The D2 or R2 dissection because worldwide, particularly in the Far East and particularly in Japan, this has been the standard of care for 30 years. That you do an extensive en bloc nodal dissection, taking the nodes down to the celiac access. You skeletonize the celiac access. There have been data presented over the years, and this is from about ten years ago, from a Japanese surgeon – Dr. Moriama – comparing United States survival and Japanese survival after gastric cancer surgery. As you see here, if you look at particularly stage III node-positive patients, you see significant differences with the Japanese patients appearing to do significantly better. Now when you see that kind of data you can say, “Well, it’s probably because the operation is better and cures more people.” Or you could say that if you don’t do the right kind of operation, what can happen is that you under-stage the patient and therefore the patients that you think are stage II are actually mostly stage III. Therefore you don’t have correct staging and you would expect the patients to do worse, stage for stage. That question is being addressed now in a number of clinical trials. These are data, more recent data, from a U.S. surgeon in Hawaii, Scott Hundal – who is a very meticulous gastric cancer surgeon and does the Japanese D2 dissection – and he just looked at data on survival from Japan, from Germany and the U.S. Again, when you look out here that’s where you see the difference, in the stage IIIa and IIIb, which are the patients who are node-positive. And it appears that the Japanese and the German patients – and in Europe the D2 dissection is more commonly done – appear to do better.
Gastric cancer
Well, what about symptoms and diagnosis of gastric cancer? With most GI cancers the symptoms of the tumor are either related to bleeding, since all GI cancers, all carcinomas of the GI tract, begin in the mucosa. So you can get irritation in the mucosa, ulceration, what have you, and bleeding. Or the other symptom is an alteration of function. What kinds of alterations of functions can you have? Well, if you have a cardioesophageal junction lesion you can have obstruction. If you have a big lesion in the stomach, you can have early satiety if the stomach is half full of tumor so it doesn’t fill with food very well. And if you have a distal gastric cancer you can have gastric outlet obstruction. So bleeding and symptoms of obstruction or early satiety are the common things that people feel. Now the kind of bleeding you get with adenocarcinomas of the stomach is rarely if ever exsanguinating hemorrhage. If you have somebody who is bleeding massively in the ER in the upper GI tract, they are bleeding from ulcers, they are bleeding from gastritis, they are bleeding from varices, but they are not bleeding from adenocarcinoma of the stomach. There is one tumor of the stomach that will bleed massively and that’s leiomyosarcoma. Of course to make things interesting for people taking the Boards, we have changed the name of leiomyosarcoma in the last four or five years to gastrointestinal stromal tumor, so GIST. But those are the tumors that can bleed massively. If you look at the frequency of symptoms, and this has to do with early diagnosis, they are relatively non-specific; some weight loss, some abdominal pain and it’s not a direct, specific symptoms of gastric cancer. In my experience, nausea, sort of unexplained vague nausea as an early symptom is a common symptom. When you talk to people who have been diagnosed with gastric cancer and you find that they sort of modified what they ate. Sometimes they changed the timing of their meals because they sometimes felt a little bit nauseated after meals.
Canadian viagra without prescription.
This is just an endoscopic ultrasound just to show you an ultrasound of the stomach. Because this is an increasing important technique used in managing patients with gastric cancer, it becomes particularly important because, as you will see, we are beginning to use a fair amount of neoadjuvant therapy. When you use neoadjuvant therapy you have to have some monitor of how effective the treatment is going to be. You also want to know what you are starting with. This endoscopic ultrasound just shows you the various layers of a normal stomach. Endoscopic ultrasound is very effective at staging the tumor. The next is an esophageal picture with the tumor here disrupting the layers of the mucosal and submucosal layers of the esophagus. But it’s very effective at staging, so you see endoscopic ultrasound used quite frequently. And of course in other GI situations, like when you are looking for the conservative therapy of rectal cancer, endoscopic ultrasound is very useful in tumor staging.
You don’t have to read this, but just to remind you that H. pylori is treatable with canadian antibiotics and typically today we use macrolides like azithromycin and bismuth compounds. And you can rid the stomach of H. pylori. This may be important in a chemo-prevention sense. In the Southwest Oncology Group we are working with a group of physicians at the Samsung Medical Center in Seoul Korea on a pilot project which is looking at a high at-risk population for gastric cancer. There is a very high incidence of gastric cancer in Korea. And randomizing patients to eradication of H. pylori and no H. pylori treatments. So this is obviously a chemo-prevention model. First we will look at whether the gastritis is significantly modified with H. pylori. The gastritis could be thought of, in a sense, as a surrogate marker for the eventual development of cancer. If this model proves to be of value – in other words, treating populations at risk with antibiotics to eradicate H. pylori – as is typical in medicine there is the law of unintended consequences. That will mean that A, a lot of people can’t afford the right antibiotics in countries where they would need them most, and B, if it is used – the antibiotic therapy is used widely – we obviously will be introducing sort of an evolutionary pressure on the bacteria to become resistant.
Viagra professional online without prescription .
What about other etiologies of gastric cancer? Prior gastrectomy is one. I’m sure most of you have not seen many patients who have had partial gastrectomies for ulcer disease in the past. Twenty-five years ago when I was training that was quite common. People did antrectomies and vagotomies and pyloroplasties to essentially decrease the gastric acid production in patients with ulcers. And it is known that there is an increased risk of gastric cancer after those procedures. The latent period is greater than 15 years. It appears that what happens is, that by decreasing … what you are doing is setting up chronic gastritis picture by decreasing the gastric acid. Now why this may be important to us is that of course the most widely prescribed, and now over-the-counter, the most widely used drugs in the pharmacopeia are H2 blockers and various ways of controlling gastric acid. And it’s possible, although we haven’t seen it yet – I’ll address it in a little bit – it’s possible that long term use – we are talking about a 15 year latency period here for gastric acid surgery – it’s possible that we will an increase in gastric cancer in people who have spent a lot of time on H2 blockers or Prilosec. So it’s something to look for in the future.
Now H2 antagonists, were thought of as, “Gee, if we make the stomach achlorhydric do we increase the risk of gastric cancer?” and short term risk has been looked at, actually. This is an article from almost ten years ago now and there was an increased risk of gastric cancer within five years of going on H2 antagonists, and the situation here was thought to be that the reason was; these patients had trouble with their stomachs, they took H2 blockers like everybody with trouble with their stomachs would. Some of the people who had trouble with their stomachs actually had premalignant conditions and had a developing gastric cancer. So people are going to watch the incidence of gastric cancer in H2 antagonists, but there is no direct connection now.
Generic pharmacy blog
Cheap canadian pharmacy
I mean, H. pylori is a very interesting organism. It’s certainly been associated with gastric ulcer disease. And you know you can treat gastric ulcers with antibiotics and H. pylori has been associated with two forms of cancer; the endemic form of gastric cancer with intestinal metaplasia and achlorhydria and it also has been associated with lymphomas, particularly the MALTomas. What do we know about H. pylori? well, it was in 1991 in this article in the New England Journal of Medicine that the first questions were really posed to a very widespread medical audience about H. pylori and gastric cancer. There were several observations made that most of the stomachs with endemic gastric cancer with intestinal metaplasia were colonized with H. pylori. Most patients with cancer were seropositive. The truth was also that most age-matched controls, so it’s a relatively ubiquitous infection as far as being exposed to H. pylori. The other thing that’s interesting here is that H. pylori is not associated with GE junction or gastrocardial cancers. Interestingly enough, chronic gastritis with H. pylori is associated with achlorhydria. You can think of chronic gastritis with H. pylori as being almost protective for Barrett’s esophagus. It’s like a potent H2 blocker, or Prilosec in a sense. The question was, does H. pylori cause gastric cancer? And obviously this is too simplistic. I think what we know now is H. pylori is a cofactor in the causation of gastric cancer. There is an increased risk of intestinal gastric cancer, decreased risk in the cardioesophageal junction and increased risk of the mucosal-associated lymphoid tumors, or the MALTomas. And MALTomas are interesting. You actually might see a question on the Board. “Well differentiated lymphatic mucosal tumors in the stomach.” And the answer to the question is, you can treat them with antibiotics at an early form and they go away because they are polyclonal proliferations. Eventually they become monoclonal lymphomas which require chemotherapy. Most of the intestinal forms of gastric cancer, the endemic in the high incidence countries, are associated with H. pylori. Only a relatively small amount of the diffuse cancers are associated with H. pylori infection.
Disorders articles
Now it appears that H. pylori is a cofactor in producing gastritis. You get an infection with gastritis, infection, gastritis, chronic mucosal injury. The chronic mucosal injury leads to intestinal metaplasia, achlorhydria and carcinoma. There are particular strains of H. pylori which appear to be more important. There is something called the KAG-A strain of H. pylori that the infectious disease people talk about, that appears to be more virulent in producing the gastritis and higher incidence of cancer.
In gastric cancer there has been a shift from the more endemic gastric cancer, associated with the high risk countries, to an cardioesophageal junction lesion which is occurring in the United States quite frequently. And we don’t really know what the etiology of that is. The endemic form of gastric cancer are two different types of gastric cancer now that are of importance. One is the endemic form which is associated with intestinal metaplasia of the stomach, with chronic gastritis, with H. pylori infection. And the other is the proximal, poorly differentiated generally, adenocarcinoma of the cardioesophageal junction which is actually increasing in incidence. But the endemic form has gone down very significantly over the last 50 years in the United States. It looks like it clearly is related to the environment. It’s clearly related to what we put in our mouths. In the early part of this century there was no widespread use of refrigeration. Fresh fruits, fresh vegetables were not eaten very much. Things like sauerkraut, things like preserved and salted vegetables were eaten. Fresh meat was not eaten. Then in the 1920’s there was the introduction of refrigerated railroad cars and actually gastric cancer began to fall about 10-15 years after, in the early 1930’s is when it began to take its real dip. And it’s very clear that when you don’t eat highly salted meats, you don’t eat a lot of meats that are preserved with nitrites, you have a lower incidence of gastric cancers. So that’s probably the reason for the fall in the endemic form.
Viagra professional
There has been a rapid increase in incidence of gastric cancer between 1975 and 1990 in the rate per thousand of – it’s gone up about four times – of adenocarcinoma of the distal esophagus, proximal stomach in white males. This is really a very rapidly increasing tumor. It’s said that only melanoma is increasing more frequently than this tumor. And we really don’t have a good clue as to why that is. It’s most common in Caucasian men, typically between the ages of 40-70, and people who are obese, who have a history of gastroesophageal reflux disease and people who smoke cigarettes and drink some alcohol. It’s interesting that if the endemic form of gastric cancer is associated with intestinal metaplasia of the stomach – in other words, small intestinal epithelium in the stomach – this of course, which is associated with Barrett’s esophagus, is gastric metaplasia of the distal esophagus. So as a general rule, it’s not good to have the wrong mucosa in the wrong organ it appears.
Canadian pharmacy blog